(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) **EP 1 998 799 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
05.03.2014 Bulletin 2014/10

(45) Date of publication and mention of the grant of the patent:
25.12.2013 Bulletin 2013/52

(21) Application number: **07752573.1**

(22) Date of filing: **06.03.2007**

(51) Int Cl.:
C07K 16/00 *(2006.01)* ***C12P 21/08*** *(2006.01)*
C07K 1/00 *(2006.01)* ***C07K 16/28*** *(2006.01)*
C07K 16/46 *(2006.01)* ***A61K 39/395*** *(2006.01)*
A61P 35/00 *(2006.01)*

(86) International application number:
PCT/US2007/005884

(87) International publication number:
WO 2007/103470 (13.09.2007 Gazette 2007/37)

(54) **HUMANIZED ANTI-CD22 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE**

HUMANISIERTE ANTI-CD22-ANTIKÖRPER UND IHRE VERWENDUNG FÜR DIE BEHANDLUNG VON KREBS, TRANSPLANTATIONEN UND AUTOIMMUNERKRANKUNGEN

ANTICORPS HUMANISÉS DIRIGÉS CONTRE L'ANTIGÈNE CD22 ET LEUR UTILISATION À DES FINS THÉRAPEUTIQUES EN ONCOLOGIE, AINSI QUE DANS LE CADRE DE TRANSPLANTATIONS ET DE MALADIES AUTO-IMMUNES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR
Designated Extension States:
AL BA HR MK RS

(30) Priority: **06.03.2006 US 779806 P**

(43) Date of publication of application:
10.12.2008 Bulletin 2008/50

(60) Divisional application:
13159009.3 / 2 639 242

(73) Proprietor: **MedImmune, LLC**
Gaithersburg, MD 20878 (US)

(72) Inventors:
- **HILBERT, David**
  Bethesda, MD 20817 (US)
- **JONES, Tarran**
  Hertforshire WD7 8AG (GB)
- **WILLIAMS, David, G.**
  Surrey KT18 7LY (GB)

(74) Representative: **Gibbs, Richard**
Marks & Clerk LLP
Aurora
120 Bothwell Street
Glasgow G2 7JS (GB)

(56) References cited:
WO-A1-94/27638
WO-A2-03/093320
WO-A2-2007/103469
US-A1- 2003 202 975
US-A1- 2004 001 828
US-A1- 2005 118 182
US-A1- 2007 264 260

- **TUSCANO JOSEPH M ET AL: "Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts." BLOOD 1 MAY 2003, vol. 101, no. 9, 1 May 2003 (2003-05-01), pages 3641-3647, XP002540281 ISSN: 0006-4971**

Printed by Jouve, 75001 PARIS (FR)

(Cont. next page)

- O'DONNELL ROBERT T ET AL: "Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy." CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII OCT 2009, vol. 58, no. 10, October 2009 (2009-10), pages 1715-1722, XP002540282 ISSN: 1432-0851
- ENGEL P ET AL: "THE SAME EPITOPE ON CD22 OF LYMPHOCYTES MEDIATES THE ADHESION OF ERYTHROCYTES, T AND B LYMPHOCYTES, NEUTROPHILS, AND MONOCYTES" JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 150, no. 11, 1 June 1993 (1993-06-01) , pages 4719-4732, XP000999233 ISSN: 0022-1767
- TUSCANO ET AL.: 'Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficaci of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts' BLOOD vol. 101, no. 9, May 2003, pages 3641 - 3647, XP002540281
- TUSCANO ET AL.: 'Engagement of the adhesion receptor CD22 triggers a potent stimulatory signal for B cells and blocking CD22/CD22L interactions impairs T-cell proliferation' BLOOD vol. 87, no. 11, 1996, pages 4723 - 4730, XP008130974
- ENGEL ET AL.: 'The same epitope on CD22 of B lymphocytes medaites the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocytes' J. IMMUNOL. vol. 150, no. 11, 1993, pages 4719 - 4732, XP000999233